Daiichi Sankyo Company, Limited (DSKYF)
| Market Cap | 31.34B -33.8% |
| Revenue (ttm) | 13.68B +15.5% |
| Net Income | 1.50B -17.9% |
| EPS | 0.81 -16.0% |
| Shares Out | n/a |
| PE Ratio | 20.96 |
| Forward PE | n/a |
| Dividend | 0.25 (1.42%) |
| Ex-Dividend Date | Sep 29, 2026 |
| Volume | 1,300 |
| Open | 17.40 |
| Previous Close | 17.33 |
| Day's Range | 17.33 - 17.40 |
| 52-Week Range | 13.85 - 29.15 |
| Beta | -0.16 |
| Analysts | n/a |
| Price Target | n/a |
| Earnings Date | Jul 31, 2026 |
About Daiichi Sankyo Company
Daiichi Sankyo Company, Limited manufactures and sells pharmaceutical products in Japan and internationally. The company offers Enhertu for the treatment of HER2 positive and low breast cancer, HER2 positive gastric or gastroesophageal junction adenocarcinoma, and HER2 positive solid tumors; Turalio, an oral small molecule for colony stimulating factor 1 receptor, KIT proto-oncogene receptor tyrosine kinase, and FMS-like tyrosine kinase 3, as well as symptomatic TGCT; Vanflyta, a FLT3 inhibitor for the treatment of acute myeloid leukemia; Injec... [Read more]
Financial Performance
In fiscal year 2026, Daiichi Sankyo Company's revenue was 2.12 trillion, an increase of 12.55% compared to the previous year's 1.89 trillion. Earnings were 259.87 billion, a decrease of -12.13%.
Financial numbers in JPY Financial StatementsNews
Enhertu® Demonstrated Statistically Significant and Clinically Meaningful Improvement in Progression-Free Survival as First-Line Treatment of Patients with HER2 Mutant Advanced Non-Small Cell Lung Cancer in DESTINY-Lung04 Phase 3 Trial
TOKYO--(BUSINESS WIRE)--Enhertu Showed Statistically Significant & Clinically Meaningful PFS Improvement as First-Line Treatment of Patients with HER2 Mutant Advanced NSCLC.
Innovent, Daiichi Sankyo Ink China Deal For VANFLYTA Commercialization
(RTTNews) - Innovent Biologics, Inc. (01801.HK) announced on August 9, 2026, that it has entered into an exclusive agreement with Daiichi Sankyo Company (TSE: 4568) to commercialize VANFLYTA (quizarti...
Innovent Biologics Secures China Commercialization Rights For Vanflyta In Deal With Daiichi Sankyo
(RTTNews) - Innovent Biologics Inc. (IVBXF, 1801.HK) and Daiichi Sankyo (DSKYF, 4568.T) have entered into an exclusive agreement for the commercialization of Vanflyta (quizartinib) in China, Innovent ...
Innovent Biologics and Daiichi Sankyo Enter Exclusive Agreement for VANFLYTA® Commercialization in China
Collaboration to accelerate access to Vanflyta® for patients with newly diagnosed FLT3-ITD positive AML SAN FRANCISCO and SUZHOU, China, Aug. 9, 2026 /PRNewswire/ -- Innovent Biologics, Inc. (01801.HK...
Q1 2027 Daiichi Sankyo Co Ltd Earnings Presentation (Japanese) Transcript
Q1 2027 Daiichi Sankyo Co Ltd Earnings Presentation (Japanese) Transcript
Daiichi Sankyo Reports First Quarter Fiscal Year 2026 Financial Results
TOKYO--(BUSINESS WIRE)--Daiichi Sankyo (TSE: 4568) reported financial results for the first quarter of fiscal year 2026, ending June 30, 2026. “Daiichi Sankyo delivered strong revenue growth in the fi...
Daiichi Sankyo Company Earnings Call Transcript: Q1 2027
Revenue surged 21% YoY in Q1 FY 2026, driven by ENHERTU and DATROWAY, but operating profit fell due to restructuring costs and inventory valuation losses. FY 2026 guidance was raised on strong U.S. sales and yen depreciation, with ongoing investments in operational excellence.
Daiichi Sankyo Company Quarterly report: Q1 2027
Daiichi Sankyo Company has published its Q1 2027 quarterly earnings report on July 31, 2026.
Daiichi Sankyo Company Slides: Q1 2027
Daiichi Sankyo Company has posted slides in relation to its Q1 2027 quarterly earnings report, which was published on July 31, 2026.
Trump Plans 100% Tariff on Generic Drugs From 2028
President Donald Trump said generic drug manufacturers will have two years to move production to the US or face a 100% import duty. Bloomberg's Mica Soellner reports on what could come next.
AstraZeneca, Daiichi near UK pricing deal for breast cancer drug, Bloomberg News reports
Drugmakers AstraZeneca and Daiichi Sankyo are nearing an agreement with the UK's pricing regulator for their breast cancer treatment Enhertu, Bloomberg News reported on Wednesday, citing multiple pe...
Daiichi Sankyo Showcases Progress Across Industry-Leading Oncology Portfolio with Latest Research Updates at ASCO
TOKYO--(BUSINESS WIRE)--Daiichi Sankyo (TSE: 4568) will present new clinical research across its oncology portfolio with more than 25 abstracts in multiple cancers at the 2026 American Society of Clin...
Daiichi Sankyo Europe Reaffirms Commitment to Patient-Centred Care with Extensive Data Showcase at EAS Congress 2026
MUNICH--(BUSINESS WIRE)--Daiichi Sankyo Europe (DSE) is pleased to announce its extensive scientific presence at the European Atherosclerosis Society (EAS) Congress 2026. The presentation of 15 abstra...
Daiichi Sankyo Company Earnings Call Transcript: Q4 2026
Revenue and core operating profit grew strongly in FY 2025, led by oncology, despite one-time expenses reducing operating profit. The new five-year plan targets over JPY 3 trillion revenue by FY 2030, with continued investment in oncology and innovative drug technologies.
Daiichi Sankyo Company Quarterly report: Q4 2026
Daiichi Sankyo Company has published its Q4 2026 quarterly earnings report on May 11, 2026.
Daiichi Sankyo Company Slides: Q4 2026
Daiichi Sankyo Company has posted slides in relation to its Q4 2026 quarterly earnings report, which was published on May 11, 2026.
Daiichi Sankyo Unveils New Five-Year Business Plan Focused on Oncology Leadership and Innovation
TOKYO--(BUSINESS WIRE)--Daiichi Sankyo (TSE: 4568) today revealed its next Five-Year Business Plan (FY2026 - FY2030) that outlines how the company plans to deliver more than 2.3 trillion yen in oncolo...
Daiichi Sankyo Company Transcript: Investor update
Operating profit forecast for FY 2025 was cut by JPY 106 billion due to temporary expenses from revised ADC supply plans and CMO compensation. The company is shifting to a risk-adjusted supply strategy, optimizing in-house and CMO roles, and maintaining its dividend outlook.
Daiichi Sankyo Company Slides: Investor update
Daiichi Sankyo Company has posted slides in relation to its latest quarterly earnings report, which was published on May 8, 2026.
Waiv Enters Collaboration with Daiichi Sankyo to Deliver AI-Derived Biomarkers for ADC Program
PARIS--(BUSINESS WIRE)--Waiv, formerly Owkin Dx, a Paris-based company catalyzing AI precision testing, today announced it has entered a collaboration with Daiichi Sankyo (TSE: 4568) to lead digital p...
Interna Therapeutics Announces Research Collaboration with Daiichi Sankyo to Advance MNM-Based Targeted Delivery Technologies
PETACH TIKVA, Israel, April 16, 2026 /PRNewswire/ -- Interna Therapeutics, a clinical stage biotechnology company advancing its Molecular Nano Motor (MNM) intracellular delivery platform, today announ...
Wayfinder Biosciences Advances Collaboration with Daiichi Sankyo on Key Neurodegeneration Target to Second Phase
SEATTLE, April 15, 2026 /PRNewswire/ -- Wayfinder Biosciences, a biotechnology company using small molecules to target undruggable proteins at the RNA level, today announced the advancement to the sec...
4D Path Announces Collaboration with Daiichi Sankyo to Advance AI-Driven Predictive Biomarkers for an Antibody Drug Conjugate Program
NEWTON, Mass.--(BUSINESS WIRE)-- #4DPath--4D Path Announces Collaboration with Daiichi Sankyo to Advance AI-Driven Predictive Biomarkers for an Antibody Drug Conjugate Program.
Voro Therapeutics Announces Research Collaboration with Daiichi Sankyo to Advance PrimeBody™ Technology for Next-Generation Tumor-Activated ADCs
SAN DIEGO--(BUSINESS WIRE)--Voro Therapeutics, a biotechnology company pioneering tumor-activated biologics using its proprietary PrimeBody platform, today announced a research collaboration with Daii...
Nikkei Rises 1.1%, Led by Shipping, Financial Stocks
Japanese stocks were broadly higher as overnight declines in crude oil prices ease fears about energy costs amid the Middle East conflict.